New steroids and new salicylates in inflammatory bowel disease: a critical appraisal (Q28192793)

inflammatory bowel diseases

Europe PubMed Central

title

New steroids and new salicylates in inflammatory bowel disease: a critical appraisal (English)

0 references

main subject

0 references

author name string

M Campieri

series ordinal

1

0 references

language of work or name

English

0 references

publication date

May 2002

0 references

published in

Gut

0 references

volume

50 Suppl 3

0 references

issue

Supplement 3

0 references

page(s)

III43-6

0 references

cites work

Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Frequency of glucocorticoid resistance and dependency in Crohn's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

An experiment to determine the active therapeutic moiety of sulphasalazine

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

National Cooperative Crohn's Disease Study: results of drug treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Mesalamine and relapse prevention in Crohn's disease

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Oral budesonide in active Crohn's disease.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

5-Aminosalicylic Acid as Enemas or Suppositories in Distal Ulcerative Colitis?

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867683

Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group

27 November 2018

1 reference

12 December 2020

Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis

1 reference

12 December 2020

Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group

1 reference

12 December 2020

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI

1 reference

12 December 2020

European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment

1 reference

12 December 2020

Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis

1 reference

12 December 2020

5-Aminosalicylic acid suppositories in the management of ulcerative colitis

1 reference

12 December 2020

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

12 December 2020

Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)

1 reference

12 December 2020

A comparison of budesonide with prednisolone for active Crohn's disease

1 reference

12 December 2020

Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration

1 reference

12 December 2020

Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group

1 reference

12 December 2020

Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease

1 reference

12 December 2020

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

1 reference

12 December 2020

Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis

1 reference

12 December 2020

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

1 reference

12 December 2020

Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis

1 reference

12 December 2020

10.1136/GUT.50.SUPPL_3.III43

Identifiers

DOI

1 reference

933534

933534

1 reference

1 reference

1 reference